摘要
目的探讨美罗华鞘注治疗中枢神经系统非霍奇金淋巴瘤的有效性和安全性。方法3例（1例原发，2例继发）具有中枢神经系统侵犯和对化疗耐药的复发性非霍奇金B细胞淋巴瘤（B细胞NHL）患者，接受了鞘内注射美罗华（intrathecal rituximab，IT RTX）治疗；采用RTX递增剂量20～50mg，每周1次，连续6～8周用药。结果在应用药物第2～3周后患者临床症状明显改善，脑脊液（CSF）中淋巴细胞清除，治疗后2个月行头颅MRI扫描显示，脑膜或者脑实质内淋巴瘤浸润性病灶明显缩小或者消失。结论结果表明IT RTX方法治疗难治／复发性中枢神经系统B细胞NHL是安全、有效的。
Objective To investigate the efficiency and safety of the treantment with intrathecal Rituximab in B-cell NHL infiltrating the central nervous system. Methods Three patients with relapsed B cell non-Hodgkin lymphoma（NHL） infiltrating the central nervous system（CNS） and resistant to chemotherapy were treated with intrathecal Rituximah（IT RTX） ,administered weekly for 6-8 weeks at increasing doses from 20-50mg. Results After the third week,the patients showed significant improvement of the clinical symptom and cerebro spinal fluid（CSF） clearance of lymphomatous cells. Two months later, the images of MRI scan showed full regression of lymphomatous infiltrational focuses. Conelousion Our report comfirms the efficacy and safety of IT RTX in the treatment of B-cell NHL in CNS,especially in relapsed or refractory patients.
出处
《重庆医学》
CAS
CSCD
2007年第20期2059-2061,F0004,共4页
Chongqing medicine
